drugset / Trial / NCT03601442

Managed Access Programs for CTL019, Tisagenlecleucel

NCT03601442

Expanded access Available Novartis Pharmaceuticals

Summary

The purpose of this registration is to list Managed Access Programs (MAPs) related to CTL019, Tisagenlecleucel

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background Tisagenlecleucel Cell therapy

Indications